🏛️ Verified NIH Record • Updated 2026-02-12
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation (NCT06778863)
GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Clasp Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- HonorHealth Research Institute — Scottsdale, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- USC - Norris Comprehensive Cancer Center — Los Angeles, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- University of California San Francisco — San Francisco, California
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- The University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- University of Kentucky Markey Cancer Center — Lexington, Kentucky
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- Hackensack University Medical Center — Hackensack, New Jersey
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- Thomas Jefferson University, Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- Mary Crowley Cancer Research — Dallas, Texas
- Baylor University Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (617) 812-1431
Email: LHarshman@clasptx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.